Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Oncolytics Biotech ( (TSE:ONC) ) has issued an announcement.
On January 22, 2025, Oncolytics Biotech announced new efficacy and safety data for pelareorep, an immunotherapeutic agent used in combination therapies for anal and pancreatic cancers, at the 2025 ASCO GI Symposium. The data showed significant improvements in treatment outcomes, with pelareorep demonstrating a strong safety profile and potential synergies with existing cancer treatments. This development could advance pelareorep-based therapies into registration-enabling studies, offering new treatment options for patients with challenging cancer indications.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company specializing in the development of pelareorep, an intravenously delivered immunotherapeutic agent. The company focuses on immunotherapy for oncology, with pelareorep demonstrating promising results in various cancers, including metastatic breast and pancreatic cancer.
YTD Price Performance: -10.11%
Average Trading Volume: 1,074,087
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $63.69M
Learn more about ONC stock on TipRanks’ Stock Analysis page.
